Suppr超能文献

截至 2021 年初,我们对 COVID-19 疫苗的了解和尚未了解的情况。

What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.

机构信息

Division of Infectious Diseases, Department of Internal Medicine, Bucheon St. Mary's Hospital, Bucheon, Korea.

Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

J Korean Med Sci. 2021 Feb 8;36(6):e54. doi: 10.3346/jkms.2021.36.e54.

Abstract

Coronavirus disease 2019 (COVID-19), which started at the end of 2019 and has spread worldwide, has remained unabated in 2021. Since non-pharmaceutical interventions including social distancing are facing limitations in controlling COVID-19, additional absolute means to change the trend are necessary. To this end, coronavirus-specific antiviral drugs and vaccines are urgently needed, but for now, the priority is to promote herd immunity through extensive nationwide vaccination campaign. In addition to the vaccines based on the conventional technology such inactivated or killed virus or protein subunit vaccines, several vaccines on the new technological platforms, for example, nucleic acids-based vaccines delivered by viral carriers, nanoparticles, or plasmids as a medium were introduced in this pandemic. In addition to achieving sufficient herd immunity with vaccination, the development of antiviral treatments that work specifically against COVID-19 will also be necessary to terminate the epidemic completely.

摘要

2019 年底开始并在全球范围内传播的 2019 冠状病毒病(COVID-19)在 2021 年仍未得到控制。由于包括社交距离在内的非药物干预措施在控制 COVID-19 方面面临限制,因此需要采取其他绝对措施来改变这种趋势。为此,急需针对冠状病毒的抗病毒药物和疫苗,但目前的当务之急是通过广泛的全国性疫苗接种运动来促进群体免疫。除了基于传统技术(例如灭活或杀死的病毒或蛋白亚单位疫苗)的疫苗外,在此次大流行中还引入了几种基于新技术平台的疫苗,例如,病毒载体、纳米颗粒或质粒作为载体的核酸疫苗。除了通过接种疫苗实现足够的群体免疫外,还需要开发专门针对 COVID-19 的抗病毒治疗方法,以彻底终止疫情。

相似文献

2
Promise and challenges in the development of COVID-19 vaccines.新冠疫苗研发的前景与挑战。
Hum Vaccin Immunother. 2020 Nov 1;16(11):2604-2608. doi: 10.1080/21645515.2020.1787067. Epub 2020 Jul 23.
3
COVID-19 Vaccines Based on Adenovirus Vectors.基于腺病毒载体的新冠病毒疫苗
Trends Biochem Sci. 2021 May;46(5):429-430. doi: 10.1016/j.tibs.2021.03.002. Epub 2021 Mar 14.
9
Coronavirus Disease 2019 Vaccine Development: An Overview.新型冠状病毒肺炎 2019 疫苗研发:概述。
Viral Immunol. 2021 Apr;34(3):134-144. doi: 10.1089/vim.2020.0119. Epub 2020 Sep 23.

引用本文的文献

2
Evaluation of patients of vaccine side effects after the COVID-19 vaccine.评价 COVID-19 疫苗接种后的疫苗副作用患者。
Rev Assoc Med Bras (1992). 2023 Feb 17;69(1):147-152. doi: 10.1590/1806-9282.20221035. eCollection 2023.

本文引用的文献

9
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验